What is TVTX's P/E ratio?

Travere Therapeutics Inc (TVTX) currently trades at a P/E ratio of 182.78.

Travere Therapeutics Inc reports a Return on Equity (ROE) of -21.70%.

What is TVTX's dividend yield?

Travere Therapeutics Inc offers a dividend yield of 0.00%.

What is TVTX's Quality Score?

Our AI rates TVTX's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy TVTX?

Our AI Timing Score for TVTX is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does TVTX belong to?

Travere Therapeutics Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Travere Therapeutics Inc (TVTX) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

TVTX AI Analysis Summary

Our AI summary for TVTX: Travere Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 182.78, ROE of -21.70%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

TVTX

Travere Therapeutics Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 86

USD 54.98

-0.91 (-1.63%) Day Change

Watchlist Portfolio Compare Chart

182.78

P/E

3.22

D/E

-21.7%

ROE

-3.9%

ROA

0.00%

Div Yield

41.83

PEG

TRAVERE THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 54.98 Price -0.91 (-1.63%) Day Change	NEWS SCORE: 86

TVTX, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...

Loading chart...

54 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	86
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	54.98
PBV / Sector	52.64 / 44,219.29
Earning Per Share	-0.23

PE / Sector	182.78 / 19.28
PEG or PE/Growth / Sector	41.83 / 1.23
Average 1M Daily Value	69.29 M
Average 1W Daily Value	73.65 M

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-4.00 / 98.22
NPM Average (%) / Sector	-95.64 / -1,697.63
NPM Change Average (%) / Sector	-27.39 / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-3.86 / 185,260.96
ROA Average (%) / Sector	-23.55 / 36,684.70
ROA Change Average (%) / Sector	29.15 / 422,221.66 GREAT
ROE (%) / Sector	-21.70 / 243,762.23
ROE Average (%) / Sector	-258.72 / 48,758.47
ROE Change Average (%) / Sector	172.82 / 424,968.10 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.19

Registration Details

Analyze Date	2026-08-04 08:02:17
Symbol	TVTX
Name	TRAVERE THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	92.99 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	5,197.37 / 9,645.64

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 3611 Valley Centre Drive, San Diego, CA, United States, 92130

Phone: 888 969 7879

Website: https://travere.com

Employees: 497

Sector: Healthcare >> Biotechnology

Description: Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.